Corcept Therapeutics (CORT) Tops Q4 EPS by 3c; Issues Light FY16 Revenue Outlook
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $79.85 +0.18%
EPS Growth %: -96.6%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: -96.6%
Financial Fact:
Research and development: 7.05M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.01, $0.03 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $15 million versus the consensus estimate of $15.5 million.
GUIDANCE:
Corcept Therapeutics sees FY2016 revenue of $76-81 million, versus the consensus of $83.3 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- BofA lists top 5 themes driving next $1tn in incremental semi sales
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
